4.Loss per share | | | | | | | For the Three Months | | | Ended June 30, | In CHF thousands except for share and per share data | | 2025 | | 2024 | Loss per share (EPS) | | | | | Numerator | | | | | Net loss attributable to equity holders of the Company | | (21,189) | | (22,760) | Denominator | | | | | Weighted-average number of shares outstanding used to compute EPS basic and diluted attributable to equity holders | | 100,631,371 | | 99,549,910 | Basic and diluted loss per share for the period attributable to equity holders | | (0.21) | | (0.23) |
| | | | | | | For the Six Months | | | Ended June 30, | In CHF thousands except for share and per share data | | 2025 | | 2024 | Loss per share (EPS) | | | | | Numerator | | | | | Net loss attributable to equity holders of the Company | | (40,218) | | (40,622) | Denominator | | | | | Weighted-average number of shares outstanding used to compute EPS basic and diluted attributable to equity holders | | 100,519,884 | | 99,467,690 | Basic and diluted loss per share for the period attributable to equity holders | | (0.40) | | (0.41) |
In periods for which AC Immune has a loss, basic net loss per share is the same as diluted net loss per share. The Company has excluded from the calculation of diluted loss per share all potentially dilutive in-the-money share options. See “Note 12. Share-based compensation” for the potentially dilutive equity awards.
|